Joe Biden's cancer moonshot might not be as far-fetched as you think. Because multiple U.S. agencies recently took steps to make the cancer moonshot a reality by further strengthening patent rights. Earlier this summer, the Patent and Trademark Office created an expedited review process for certain patent applications covering "immunotherapies" -- new cancer treatments that re-engineer the body's immune system to attack tumors. Within days, the National Institutes of Health rejected a petition that urged the agency to use "march-in" rights to effectively take back the patent on a prostate cancer drug: It would've had a chilling effect on the development of new drugs if such blatant government overreach was implemented. Fortunately, both moves reaffirmed researchers' faith in the patent system, giving companies the confidence to continue investing in cancer research and countless other medical innovations.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We collaborate with the world for the health of everyone in it. Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses.
In 2011, developer and researcher Alexandra Elbakyan launched Sci-Hub, an online archive that shares research articles freely and openly without paywalls or restrictions. Four years later, as the archive passed 48 million articles, academic publishing giant Elsevier filed a copyright infringement claim against the site. Sci-Hub has ignored an injunction to stop distributing copyrighted articles because it is hosted in Russia, beyond the influence of the US courts. A March 17 hearing offered little change to stem the flow of research articles flowing from Sci-Hub to eager researchers. Ryan Merkley is the CEO of Creative Commons, a global nonprofit that enables the sharing and use of creativity and knowledge through free legal tools.
Even just a generation ago, the concept of a handheld device able to talk back to you was a fantasy, but it's now something that even toddlers are used to. Besides all the fanfare, there are some very real-world changes AIs are making, especially in the job market. While they offer us new opportunities for innovation, they take away some of our most grounded and trusted security nets.Is artificial intelligence a step in the right direction, or the beginning of a dystopia? Here are the pros and cons of AI's influence on the job market: While AIs take away some jobs, as we've all heard, they also create them in the process. With the creation of the self-driving car, the need for taxi drivers will decrease; however, the need for those who can design such cars, gather data on their effectiveness, and create interactive systems to customize the user's experience are suddenly in demand.
AI and Machine Learning were two of 2017's hottest technological buzzwords. It's not difficult to understand why: the potential benefits of these technologies are exciting and profound. But artificial intelligence and machine learning both rely on other foundational technologies in order to achieve the results that they promise. Consequently, innovation within the realm of AI is constrained by the limitations of other technologies.